ABSTRACT
BACKGROUND: MAGE genes encode for tumor-rejection antigens and are expressed in tumors of different histologic types but not in normal tissues, with the exception of testis and placenta. The aim of this study was to evaluate the frequency of MAGE-1 and -2 expression in gastric and in cardial carcinomas; these conditions have been described as two distinct diseases, having different etiologies, epidemiologic patterns, and gene mutations. METHODS: Two groups of patients were studied: patients with distal gastric carcinoma and patients with carcinoma of the cardia. A group of patients with intestinal metaplasia in the gastric mucosa and controls were also included. All of them underwent upper GI endoscopy. Paired biopsy specimens were taken for routine histology and for RNA extraction, to study the expression of MAGE-1 and -2 genes. RESULTS: None of the intestinal metaplastic samples or controls expressed MAGE-1 and -2 at detectable levels. Whereas 40% of the gastric cancer patients expressed either MAGE-1 or -2, 26.6% transcribed both. In the cardial cancer group, 20% of the cases expressed at least one MAGE, and only 6.6% expressed both genes. These results might reinforce the concept that cancer of the cardia is a distinct neoplastic disease with regard to esophageal and gastric (distal) carcinomas. CONCLUSIONS: Here we show that MAGE gene expression occurs in advanced stages of gastric and cardial cancer and therefore appears to be a late event. This might point to a reconsideration of their potential role in cancer immunotherapy.
Subject(s)
Antigens, Neoplasm/genetics , Cardia , Gene Expression Regulation, Neoplastic , Neoplasm Proteins/genetics , Stomach Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Cancer Vaccines , Female , Humans , Intestine, Small/pathology , Male , Melanoma-Specific Antigens , Metaplasia , Middle Aged , Molecular Sequence Data , Polymerase Chain ReactionABSTRACT
BACKGROUND: The role of growth factors/receptors in the etiopathology and/or development of gastric cancer has recently come under scrutiny, since overexpression or amplification of the EGF system has been found in many intestinal type gastric cancers and related to a more aggressive behavior. Since these gastric carcinomas appear to develop from intestinal metaplasia, a study was planned to investigate whether overexpression of the EGF-receptor gene also occurred in intestinal metaplastic mucosa. METHODS: Patients underwent upper GL endoscopy. Gastric biopsies for routine histology, Helicobacter pylori detection, quantification of intestinal metaplasia and EGF-R expression analysis were performed. A 30mer EGF-R specific oligonucleotide was end-labeled and used to probe a dot blot filter containing the RNA from the bioptic samples. RESULTS: Though all the gastric samples transcribed the EGF-R gene to a detectable level, overexpression of the EGF-R gene was found in the metaplastic mucosa in a minority of patients. CONCLUSIONS: These preliminary findings suggest that overexpression of the EGF-R gene is infrequent in the metaplastic gastric mucosa.
Subject(s)
ErbB Receptors/biosynthesis , ErbB Receptors/genetics , Gastric Mucosa/metabolism , Gene Expression , Intestinal Mucosa/metabolism , RNA/analysis , Aged , Biopsy , Blotting, Northern , Chronic Disease , Female , Gastric Mucosa/pathology , Gastritis/complications , Gastritis/pathology , Gastroscopy , Humans , Intestines/pathology , Male , Metaplasia/complications , Metaplasia/metabolism , Metaplasia/pathology , Middle Aged , Oligonucleotide Probes/chemistrySubject(s)
Esophagoscopy/methods , Esophagus , Foreign Bodies/therapy , Gastroscopes , Stents/adverse effects , Cardia , Corrosion , Equipment Failure , Esophageal Stenosis/therapy , Foreign Bodies/diagnostic imaging , Gastroscopy/methods , Humans , Radiography , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/therapyABSTRACT
Whether to palliate dysphagia in patients with inoperable cancer of the cervical esophagus is a debatable issue. We report herein a patient who underwent definitive chemoradiotherapy for cancer of the cervical esophagus, with early recurrence of dysphagia 1 month after the end of the treatment. No salvage surgery was attempted due to the poor general conditions and to the residual effects of the radiotherapy in the neck. Endoscopically, the upper esophageal sphincter (UES) was located 17 cm from the incisors, and the cranial margin of an infiltrating stricture was just 1 cm below the sphincter. After endoscopic dilatation, a self-expanding esophageal prosthesis (Ultraflex, Microvasive, USA) was placed under endoscopic and radiologic control with the cranial margin at the level of the UES. The patient promptly resumed oral feeding and 2 months later he is still on unrestricted diet.
Subject(s)
Carcinoma, Squamous Cell/therapy , Esophageal Neoplasms/therapy , Palliative Care , Prostheses and Implants , Deglutition Disorders/therapy , Esophagoscopy , Humans , Male , Middle Aged , StentsABSTRACT
The use of inflatable intragastric balloons is a new non-intensive approach in the treatment of obesity when poor results are obtained by more conservative treatment. The intragastric balloons are certainly less hazardous than bariatric surgery but their long term effect on body-weight reduction it is not still proved. Several types of balloons are currently in use. The two used most widely are the Garren-Edwards Gastric Bubble and the Ballobes Balloon. The Authors report their experience with these two types of anti-obesity gastric-balloon in 60 grossly obese patients.
Subject(s)
Gastric Balloon , Obesity/therapy , Evaluation Studies as Topic , Gastric Balloon/adverse effects , HumansSubject(s)
Adenoma/surgery , Colorectal Neoplasms/surgery , Adenoma/pathology , Adult , Aged , Colorectal Neoplasms/pathology , Humans , Methods , Middle AgedSubject(s)
Anti-Ulcer Agents/therapeutic use , Duodenal Ulcer/drug therapy , Duodenitis/drug therapy , Fatty Acids/therapeutic use , Gastritis/drug therapy , Prostanoic Acids/therapeutic use , Stomach Ulcer/drug therapy , Double-Blind Method , Duodenoscopy , Gastroscopy , Humans , Ranitidine/therapeutic useSubject(s)
Anti-Anxiety Agents/administration & dosage , Benzodiazepines , Diazepam/analogs & derivatives , Diazepam/administration & dosage , Endoscopy , Nordazepam/analogs & derivatives , Premedication , Adolescent , Adult , Aged , Double-Blind Method , Female , Humans , Injections, Intravenous , Male , Middle Aged , Nordazepam/administration & dosageABSTRACT
Ulcerative colitis with malignant degeneration and dysplasia can be a precancerous lesion. Therefore, it is necessary to prevent or, at least to diagnose as early as possible any development toward neoplasia in the colon or rectum of the colitis patients. The only reliable guide for a risk of malignant tissue degeneration is dysplasia of the mucosa. A group of 31 patients was studied after total colectomy with ileorectal anastomosis and subsequent topical treatment with enemas containing sulphasalazine and corticosteroids. Two of these patients had mild rectal dysplasia before surgery, seen in a biopsy specimen obtained endoscopically. All the patients were followed for a long time after surgery, with endoscopy and microscopic and ultrastructural observation of rectal biopsy material taken from different sites in the mucosa, both from areas that looked dysplastic by endoscopy and from those that appeared normal. The two patients with presurgical dysplasia, when examined later, one 12 months and one 18 months after surgery, had no rectal dysplasia; the mucosal covering was moderately complete and the anastomosis was functioning. It is considered that to prevent development of cancer in the rectal stump, colectomy should always be followed by regular topical treatment and there should be a check-up at short intervals for early diagnosis of any premalignant areas that might develop. Regression of such lesion was observed to lesser degrees after continuous treatment with the topical medication.
